Huntington’s Disease: A General Overview
DOI:
https://doi.org/10.62051/gjkq6086Keywords:
Huntington’s Disease; neurodegenerative disorder; cytosine-adenine-guanine repeat disorders, movement disorders.Abstract
This article overviews Huntington’s Disease (HD), emphasizing the development of neuroimaging biomarkers, pathogenesis discovery, and clinical treatment. The fundamental knowledge of HD includes its definition, diagnosis as an etiological subtype of neurodegenerative diseases in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), clinical neuropsychiatric symptoms, and social impact. The development of neuroimaging biomarkers is discussed with different developmental stages of HD. Mental health issues in the HD population including depression, anxiety, and psychosis were reviewed. The suicidal rate in this population is alarming, indicating the necessity to make both medical and mental health services available. Clinical treatments, including pharmacological and non-pharmacological, are overviewed with the timeline from now till the future. Recommendations are given for refining current research and future research design regarding neuroimaging biomarker exploration, early diagnosis, and potential treatment investigation. This review can provide some guidance to the development of more advanced diagnostic tools and effective treatments for this population.
Downloads
References
Roos R. A. Huntington's disease: a clinical review. Orphanet journal of rare diseases, 2010, 5: 1-8.
Walker F. O. Huntington's disease. The Lancet, 2007, 369(9557): 218-228.
Sachdev P. S., Mohan A., Taylor L., Jeste D. V. DSM-5 and mental disorders in older individuals: an overview. Harvard review of psychiatry, 2015, 23(5): 320.
Paulsen J. S., Ready R. E., Hamilton J. M., Mega M. S., Cummings J. L. Neuropsychiatric aspects of Huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry, 2001, 71(3): 310-314.
Schoenfeld M., Myers R. H., Cupples L. A., Berkman B., Sax D. S., Clark E. Increased rate of suicide among patients with Huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry, 1984, 47(12): 1283-1287.
Frank S. Treatment of Huntington’s disease. Neurotherapeutics, 2014, 11: 153-160.
Ross C. A., Tabrizi S. J. Huntington's disease: from molecular pathogenesis to clinical treatment. The Lancet Neurology, 2011, 10(1): 83-98.
Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D., Richardson Jr E. P. Neuropathological classification of Huntington's disease. Journal of Neuropathology & Experimental Neurology, 1985, 44(6): 559-577.
Weir D. W., Sturrock A., Leavitt B. R. Development of biomarkers for Huntington's disease. The Lancet Neurology, 2011, 10(6): 573-590
Van Eimeren T., Giehl K., Reetz K., Sampaio C., Mestre T. A. Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development. Parkinsonism & Related Disorders, 2023, 105488.
Tobin A. J., Signer E. R. Huntington's disease: the challenge for cell biologists. Trends in cell biology, 2000, 10(12): 531-536.
Di Maio L., Squitieri F., Napolitano G., Campanella G., Trofatter J. A., Conneally P. M. Suicide risk in Huntington's disease. Journal of medical genetics, 1993, 30(4): 293-295.
Farrer L. A., Opitz J. M., Reynolds J. F. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. American journal of medical genetics, 1986, 24(2): 305-311.
Dewhurst K., Oliver J. E., McKnight A. L. Socio-psychiatric consequences of Huntington's disease. The British Journal of Psychiatry, 1970, 116(532): 255-258.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
